The analysis — commissioned by the Pharmaceutical Care Management Association, a major PBM lobby group — assessed gross and net sales data for 200 self-administered, patent-protected brand name drugs.
The report found many higher-than-average price increases occurred in drug categories where pharmaceutical companies negotiated fairly low rebates with PBMs. The researchers also noted there were lower-than-average price hikes for drugs where pharmaceutical companies negotiated relatively high rebates with PBMs.
“This study debunks the notion that the prices drugmakers set are contingent on the rebates they negotiate with PBMs,” Mark Merritt, president and CEO of PCMA, said in a statement. “Ironically, many higher priced drugs involve little or no such rebates.”
To read the full report, click here.
More articles on supply chain:
Global pharmerging market to reach $1.4B by 2025
FDA OKs Tecentriq for advanced bladder cancer
Medtronic sells majority of medical supplies unit to Cardinal for $6.1B
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
